

Supplemental Table 5 Effect of treatment on size and proliferation of renal tumour cells in *Tsc2*^{+/-} mice

(Wilcoxon rank-sum test)

A. Size of tumour cells

Treatment*	Number of tumours examined	Median (μm^2)	Range (μm^2)	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	25	184.150	152.070-214.594		
Everolimus	25	77.837	52.238-119.970	6.063 (0.0001)	2.513 (0.0120)
Sorafenib	25	165.110	133.804-225.855	2.163(0.0305)	6.063 (0.0001)
Everolimus + Sorafenib	25	66.554	37.850-95.809	6.063 (0.0001)	

B. Percentage of tumour cells positive for Ki67

Treatment*	Number of tumours examined	Median (%)	Range (%)	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	25	18.784	10.268-32.155		
Everolimus	25	0.329	0.000-1.333	6.106 (0.0001)	-0.339 (0.7340)
Sorafenib	25	16.230	10.263-22.079	2.047 (0.0407)	6.105 (0.0001)
Everolimus + Sorafenib	25	0.167	0.000-2.119	6.106 (0.0001)	

* Treatment was started from 11 month old and continued for two months.